Exchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
-1.74% CHF39.50
America/New_York / 30 apr 2024 @ 11:31
FUNDAMENTALS | |
---|---|
MarketCap: | 474.13 mill |
EPS: | 0.860 |
P/E: | 45.93 |
Earnings Date: | Feb 13, 2024 |
SharesOutstanding: | 12.00 mill |
Avg Daily Volume: | 0.0364 mill |
RATING 2024-04-30 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
Asset | n/a | n/a | n/a | n/a | n/a | n/a |
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
1.82x |
Company: PE 45.93 | sector: PE 25.29 |
PE RATIO: COMPANY / INDUSTRY |
---|
2.69x |
Company: PE 45.93 | industry: PE 17.08 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
CHF 38.18 - 40.82 ( +/- 3.34%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | CHF39.50 (-1.74% ) |
Volume | 0.0357 mill |
Avg. Vol. | 0.0364 mill |
% of Avg. Vol | 98.13 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.